Document is current
Any future updates will be listed below
-
Authors
Tournilhac, Olivier https://orcid.org/0000-0002-9438-621X
van Gelder, Michel
Eikema, Dirk-Jan
Zinger, Nienke
Dreger, Peter https://orcid.org/0000-0002-7429-8570
Bornhäuser, Martin
Vucinic, Vladan https://orcid.org/0000-0002-8398-285X
Scheid, Christof
Cornelissen, Jan J.
Schroeder, Thomas
Jindra, Pavel https://orcid.org/0000-0002-8415-7069
Sengeloev, Henrik
Nguyen Quoc, Stephanie
Stelljes, Matthias
Blau, Igor Wolfgang
Mayer, Jiri
Paneesha, Shankara
Chevallier, Patrice https://orcid.org/0000-0003-3142-5581
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Blaise, Didier https://orcid.org/0000-0002-5684-9447
Gribben, John https://orcid.org/0000-0002-8505-7430
Nielsen, Bendt
Johansson, Jan-Erik
Kyriakou, Charalampia
Beguin, Yves
Pioltelli, Pietro
Sampol, Antònia https://orcid.org/0000-0001-7465-6203
McLornan, Donal P. https://orcid.org/0000-0003-1224-091X
Schetelig, Johannes
Hayden, Patrick J. https://orcid.org/0000-0003-1374-4503
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
- License Information
-
More Information
Article History
Received: 6 November 2022
Revised: 5 February 2023
Accepted: 10 March 2023
First Online: 28 March 2023
Competing interests
: From: Astra-Zeneca; Abbvie; Beigene; Blueprint; Gilead; Incyte; Janssen; Roche; Sandoz; Secura-Bio: Travel grants; Research grants; Honorarium (advisory board, symposium, expertise).
